Myomo Inc. develops and markets wearable medical robotics for people with neurological disorders and upper-limb paralysis. Its MyoPro product line is a powered upper-limb orthosis that uses non-invasive EMG sensors to support weakened or paralyzed arms in patients with conditions such as stroke, brachial plexus injury, traumatic brain injury, spinal cord injury and other neuromuscular disease or injury.
Company news commonly covers MyoPro orders, insurance authorizations, patient-pipeline trends, revenue from recurring patient sources, market-access relationships with orthotics and prosthetics providers, and product-development updates such as the Myomo Mobile App. Updates also include clinical research evaluating MyoPro, operating results, direct-billing activity, international sales channels and board governance changes.
Myomo (NYSE American: MYO) appointed Mary-Katherine McClure as Chief Commercial Officer effective October 12, 2026, succeeding Micah Mitchell after a transition period. Mitchell will remain with the company until December 23, 2026. McClure joins from Inspire Medical Systems, where she had worked since 2018, and brings more than 20 years of experience.
McClure received 275,000 time-based restricted stock units, equity awards that vest subject to continued service, and 225,000 performance-based units at target. The performance award can range from 0% to 150% of target, capped at 337,500 shares. Half depends on financial metrics for 2029; half depends on relative stock-price performance. Myomo's direct provider business now represents approximately 70% of annual revenues.
Myomo (NYSE American: MYO) will participate in the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte Palace Hotel in New York from September 14–16, 2026. President and CEO Paul Gudonis and CFO David Henry will deliver a company presentation and hold one-on-one investor meetings.
The formal presentation will be available on demand starting September 11, 2026 at 7:00 a.m. ET. On September 16, 2026 at 10:30 a.m. ET, management will join a fireside chat, with a live webcast accessible via the company’s provided conference link.
Myomo (NYSE American: MYO) reported second quarter 2026 revenue of $11.7 million, up 21% year over year, with 53% of revenue from recurring referral sources via MyoConnect and other channels. The company recognized revenue on 211 MyoPro units and achieved an average selling price of about $55,500, up 2%.
Gross margin rose to 72.1% from 62.7%, lifting gross profit to $8.4 million. Operating expenses were $10.7 million, up less than 1%, driving an operating loss improvement to $2.3 million from $4.6 million and an Adjusted EBITDA loss of $0.8 million versus $4.0 million. Net loss was $4.0 million ($0.09 per share). Cash, cash equivalents and short-term investments totaled $13.5 million, with operating cash use of $1.9 million versus $8.9 million a year earlier.
Myomo raised its 2026 revenue guidance to $45–$47 million, implying approximately 10–15% growth, and guided Q3 2026 revenue to $11.5–$12.0 million, up 14–19% year over year.
Myomo (NYSE American: MYO) announced it will report second quarter 2026 financial results, for the period ended June 30, 2026, on Wednesday, August 5, 2026. Management will host a conference call at 4:30 p.m. Eastern time to review results, discuss the business and take questions.
Investors can pre-register to receive a dial-in number and PIN, or join by calling 844-707-6932 (U.S.) or 412-317-9250 (International). A live webcast and replay will be available at https://ir.myomo.com/, with dial-in replay access through August 19, 2026 using code 1135727.
Myomo (NYSE American: MYO) announced participation in two virtual investor conferences on May 20-21, 2026. President and CEO Paul Gudonis and CFO David Henry will join a fireside chat at the Alliance Global Partners Annual Healthcare Company Showcase at 11:20 a.m. ET on May 20.
CFO David Henry will also present at Sidoti’s Virtual Micro Cap Conference, with a live webcast scheduled for 1:45 p.m. ET on May 21 and one-on-one investor meetings throughout the event.
Myomo (NYSE American: MYO) appointed Joseph M. “Joe” Manko Jr. to its Board of Directors, effective May 9, 2026, serving until the 2027 annual meeting. With his addition, the board now has seven directors.
Manko, Senior Principal and founder of Horton Capital Management, a significant shareholder, brings over 25 years of experience in investment banking, private equity, asset management, corporate strategy, and corporate governance, plus prior roles at Deutsche Bank, Merrill Lynch, and Skadden Arps.
Myomo (NYSE: MYO) reported Q1 2026 revenue of $10.1M, up 3% year-over-year, with 49% of revenue from recurring patient sources. Gross margin expanded to 68.2%, operating expenses fell 1%, and Adjusted EBITDA improved to $(2.3)M. Cash and short-term investments were $15.7M. Backlog was 226 patients; 239 orders received, up 12% YoY. Company reaffirmed full-year revenue guidance of $43M–$46M and Q2 revenue outlook of $10.3M–$10.8M.
Myomo (NYSE American: MYO) announced expanded availability of the MyoPro powered arm brace through Ottobock Care clinics across the U.S. Ottobock Care will offer fittings and clinical support; Myomo says clinicians have been trained and several patients have already been fitted.
The company noted that Medicare and a growing number of insurers cover MyoPro on a case-by-case basis.
Myomo (NYSE American: MYO) will report first quarter 2026 financial results for the period ended March 31, 2026 on Thursday, May 7, 2026. Management will host a conference call at 4:30 p.m. ET to review results, provide a business update and answer questions. A webcast, live dial-in numbers, pre-registration link, and replays will be available via the investor site.
Myomo (NYSE American: MYO) launched the Myomo Mobile App on April 20, 2026 to improve clinician workflow and patient engagement for MyoPro users. The app enables remote and in-person EMG configuration, real-time muscle-activity visualizations, usage tracking, training resources, and supports expanded data capture for future analytics.